CHARLES-ANDRÉ BROUWERS – CHAIRMAN
Charles-André has thirty-year years of experience consulting to the biopharma and medical device industries. He worked closely with the CEOs, Senior Executives, and Boards of many Pharmaceutical and Medtech companies. Previous to founding Galileo Life Sciences, he was Senior Partner and Managing Director at the Boston Consulting Group and before Head of the Life Sciences Group of Capgemini.
Charles-André is a registered representative affiliated with Galileo Global Securities, LLC is a broker-dealer registered with the SEC, a member of the Financial Industry Regulatory Authority (FINRA)
Dr. BERNARD COURTIEU
Dr. Courtieu joined IntegraGen as CEO in September 2007. Prior to this, he had achieved significant success within Gemini Consulting’s Life Sciences division, France, first as Practice Leader, and later on as Vice President. Dr. Courtieu’s tenure with Eurostart, Bossard Gemini Consulting and Cap Gemini Ernst & Young resulted in much hands on experience in how to improve the operational performance of pharmaceutical companies in the fields of Research and Development, Industrial Operations, Supply Chain and Marketing and Information Systems.
Later on, Dr. Courtieu took the position as Country Manager, France, at Ariba, the world leader in spend Management, assisting companies in analyzing and managing their corporate spending to achieve maximum buisiness process efficiency. Dr. Courtieu holds an MBA from the Instituto de las Estudios Superiores de la Empresa (IESE) in Barcelona, Spain and he also received his doctorate in Veterinary Medicine from the Ecole Vétérinaire d’Alfort and University Paris XII, France.
JEAN-POL DETIFFE
Jean-Pol Detiffe is an industrial pharmacist by training with over 20 years of experience in the healthcare sector. Jean-Pol is a dynamic Belgian entrepreneur who founded OncoDNA in 2012 with the ambition to help individuals with cancer all over the world benefit from a personalized analysis of their tumor based on the latest DNA sequencing technologies.
Prior to this he founded DNAVision in 2004, the first company in Europe to provide the pharmaceutical industry with accredited pharmacogenetic tests (exit in 2012).
FRANÇOIS FONTAINE
François Fontaine holds a law degree from the University of Brussels and is specialist in Tax affairs. He was counsel in various public institutions and cabinet.
He is currently general counsel to the Federal Holding and Investment Company (SFPI)-FPIM. SFPI is focusing its investments on innovative Belgian Companies, hoping to contribute to their financial and societal success story. Mr. Fontaine is also Board member of several companies including biotechs.
FRANÇOIS BLONDEL
Graduated in Law and Economic Sciences, François Blondel combines both executive roles as CEO of KitoZyme and Delphi Genetics, as well as Executive Chairman of KiOmed Pharma, and non-executive board member positions, either as chairman of the board or as an independent member.
Throughout his career, François Blondel has (co-)founded several startups and gained solid experience in managing companies active in the field of innovation. From 1999 to 2010, he was the CEO of International Brachytherapy (IBt), a company listed on NYSE Euronext, which transitioned from a research and development stage to a diversified and thriving international group, becoming a European leader in its market.
The companies in which he is or has been active range from SMEs and spin-offs, such as OncoDNA, Nanocyl, and Delphi Genetics, active in the technological, medical, and healthcare sectors, to large publicly traded companies, like RECTICEL or the Compagnie du BOIS SAUVAGE, and public organizations such as AWEX, AMONIS, and BioWIN.
FRANÇOIS THOMAS, M.D., Ph.D
Dr. François Thomas is a medical oncologist, former assistant professor at the Gustave Roussy Institute, and holds an MBA from the Massachusetts Institute of Technology.
Dr. Thomas is in charge of the Inserm Transfer Initiative (ITI) Funds at Sofimac, where he is venture partner. His multi-disciplinary experience has led him to positions of VP Clinical Development at Ipsen, General Manager of the consultancy Bioserve Ltd, VP of Licensing and Medical Affairs of Genset, and President of Cynthéris. He has also been a venture partner at Atlas Venture and Head of Healthcare Banking at Bryan Garnier. Dr Thomas has dedicated his last 20 years to the creation and development of biotech companies and is or has been a Director for more than 20 of these companies.
